Across TCGA pan-cancer cohorts, FOXD4L4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FOXD4L4 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher FOXD4L4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FOXD4L4 expression acts as an unfavorable survival marker.
SARC are the cancer types where FOXD4L4 Mutation most reproducibly stratifies survival.